In the global oncology, docetaxel is a variety with fast development. The first product of it was developed and pushed to market by French company .Now it is sold to the markets of the U.S., Japan and more than 80 countries and regions. In the seven major pharmaceutical markets in 2005, sales of docetaxel and paclitaxel original drugs have reached more than 10% of total anti-tumor, reaching $ 2.762 billion. In the first half of 2006, the record was renewed by $ 1.545 billion.

In recent years, with the international academic community, the drug docetaxel-depth study, found that the product in prostate cancer, pancreatic cancer, soft tissue tumors, head and neck cancer, stomach cancer, esophageal cancer and other solid tumors in a significant effect, thus making it one of the drugs commonly used in clinical anti-tumor. Contains a huge market opportunity, many R & D institutions, manufacturers of the products of research and development rush, many companies follow up reporting of docetaxel drug registration.

Docetaxel are taxanes synthetic drugs in 1996, the French production of such drugs have entered China, the brand name taxotere sale, and later loaded varieties of Chinese national essential drug formulations directory and China National Basic medical insurance and industrial injury insurance drug list, its indications for use in advanced ovarian cancer, non-small cell lung cancer, breast cancer treatment.

The success of Chinese Academy of Medical Sciences docetaxel drug substance and powder for injection, the four drugs as declared in September 30, 2002 approved for production, trade name Ai Su. In 2003 the bulk drug and injection to obtain registration certificate of production, trade name Duo Pafei. Currently under the influence of the technical barriers, the relative concentration of manufacturers, SFDA approved only six companies producing docetaxel API and injections.

In 2005, the amount of docetaxel medication in the sample hospitals of China's key cities showed rapid growth. The annual amount of drugs exceeded 157 billion RMB. Comparing to the 1.07 billion RMB of the previous year, it increased by 46%. There were just 4 suppliers. China docetaxel formulations are mainly Jiangsu’s docetaxel, Shandong’s duopafei and Zhejiang’s adamssongdi. The share of three species is 65%, it dominant the Chinese market. Foreign drug irinotecan only accounted for 34.88%. From the consumption point of view, Chinese-made occupies docetaxel is 85% of the market share, foreign brand-name drugs accounted for only 14.82%. Clearly, Chinese-made drugs overwhelmingly dominated. Docetaxel in the Chinese market has become a promising variety. And it will be the most potential drug in anti-cancer chemotherapy drugs market. It also indicates that the market structure have been changed.Source:http://www.cospcn.com